CureVac NV Q3 2021 Earnings Call Transcript - Thomson StreetEvents

CureVac NV Q3 2021 Earnings Call Transcript

CureVac NV Q3 2021 Earnings Call Transcript - Thomson StreetEvents
CureVac NV Q3 2021 Earnings Call Transcript
Published Nov 19, 2021
12 pages (7797 words) — Published Nov 19, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of CVAC.OQ earnings conference call or presentation 19-Nov-21 1:00pm GMT

  
Brief Excerpt:

...Operator Greetings, and welcome to the CureVac AG Third Quarter and First 9 Months 2021 Financial Results and Business Update. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Ms. Sarah Fakih, Head of the Corporate Communications and Investor Relations for CureVac AG. Please go ahead. Sarah Fakih ...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
CureVac NV
Ticker
CVAC.OQ
Time
1:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : So I have a questions around -- also around modified, unmodified. I guess in this collaboration with GSK, what are they contributing to the second-gen effort? And just on that modified, would they be working on the unmodified mRNA together with you guys? And then I have a follow-up.

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Got it. And my second question is around the clinical development strategy here. I know it's probably early, but I'd like to ask probably for your second generation, you're looking at the booster market. I guess, in this market -- in this asset, when you run clinical trials, are you looking to vaccinate people with 2 doses? Or are you looking for people who have been vaccinated and give them a booster? And then also related to that, I know your first generation is primarily for the European market. Now with everything exchanged that are you looking at both the U.S. and the Europe market at this point?

Table Of Contents

CureVac NV at Jefferies Healthcare Conference Transcript – 2022-06-09 – US$ 54.00 – Edited Transcript of CVAC.OQ presentation 9-Jun-22 1:30pm GMT

CureVac NV at Bank of America Healthcare Conference Transcript – 2022-05-10 – US$ 54.00 – Edited Transcript of CVAC.OQ presentation 10-May-22 3:00pm GMT

CureVac NV Q4 2021 Earnings Call Summary – 2022-04-28 – US$ 54.00 – Edited Brief of CVAC.OQ earnings conference call or presentation 28-Apr-22 1:00pm GMT

CureVac NV Q4 2021 Earnings Call Transcript – 2022-04-28 – US$ 54.00 – Edited Transcript of CVAC.OQ earnings conference call or presentation 28-Apr-22 1:00pm GMT

CureVac NV Q3 2021 Earnings Call Summary – 2021-11-19 – US$ 54.00 – Edited Brief of CVAC.OQ earnings conference call or presentation 19-Nov-21 1:00pm GMT

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Summary – 2021-10-12 – US$ 54.00 – Edited Brief of CVAC.OQ conference call or presentation 12-Oct-21 1:00pm GMT

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Transcript – 2021-10-12 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 12-Oct-21 1:00pm GMT

CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call Transcript – 2021-07-01 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 1-Jul-21 12:00pm GMT

CureVac NV Updates On Clinical Trial - Corporate Call Transcript – 2021-06-17 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 17-Jun-21 12:00pm GMT

CureVac NV Q4 2020 Earnings Call Transcript – 2021-04-15 – US$ 54.00 – Edited Transcript of CVAC.OQ earnings conference call or presentation 15-Apr-21 2:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "CureVac NV Q3 2021 Earnings Call Transcript" Nov 19, 2021. Alacra Store. May 01, 2024. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q3-2021-CureVac-NV-Earnings-Call-T15052704>
  
APA:
Thomson StreetEvents. (2021). CureVac NV Q3 2021 Earnings Call Transcript Nov 19, 2021. New York, NY: Alacra Store. Retrieved May 01, 2024 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q3-2021-CureVac-NV-Earnings-Call-T15052704>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.